ZA963152B - Novel triazolones as apolipoprotein-b synthesis inhibitors. - Google Patents

Novel triazolones as apolipoprotein-b synthesis inhibitors.

Info

Publication number
ZA963152B
ZA963152B ZA9603152A ZA963152A ZA963152B ZA 963152 B ZA963152 B ZA 963152B ZA 9603152 A ZA9603152 A ZA 9603152A ZA 963152 A ZA963152 A ZA 963152A ZA 963152 B ZA963152 B ZA 963152B
Authority
ZA
South Africa
Prior art keywords
6alkyl
formula
substituted
apolipoprotein
6alkyloxy
Prior art date
Application number
ZA9603152A
Other languages
English (en)
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Paul August Clement Luyts
Didier Robert Guy G Courcelles
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA963152B publication Critical patent/ZA963152B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
ZA9603152A 1995-04-20 1996-04-19 Novel triazolones as apolipoprotein-b synthesis inhibitors. ZA963152B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95201010 1995-04-20

Publications (1)

Publication Number Publication Date
ZA963152B true ZA963152B (en) 1997-10-20

Family

ID=8220206

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9603152A ZA963152B (en) 1995-04-20 1996-04-19 Novel triazolones as apolipoprotein-b synthesis inhibitors.

Country Status (22)

Country Link
US (2) US5922718A (pt)
EP (1) EP0871626B1 (pt)
JP (1) JP3782455B2 (pt)
KR (1) KR100413219B1 (pt)
CN (1) CN1076727C (pt)
AT (1) ATE208386T1 (pt)
AU (1) AU699313B2 (pt)
CA (1) CA2217632A1 (pt)
CZ (1) CZ291737B6 (pt)
DE (1) DE69616825T2 (pt)
DK (1) DK0871626T3 (pt)
ES (1) ES2167555T3 (pt)
HK (1) HK1012186A1 (pt)
HU (1) HUP9801056A3 (pt)
IL (1) IL117980A (pt)
NO (1) NO312415B1 (pt)
NZ (1) NZ305869A (pt)
PL (1) PL183737B1 (pt)
PT (1) PT871626E (pt)
TW (1) TW457240B (pt)
WO (1) WO1996033193A1 (pt)
ZA (1) ZA963152B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1515703A1 (en) 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
ES2401645T3 (es) * 2003-06-19 2013-04-23 Merck Serono Sa Uso de agentes moduladores de la conversión de priones
EP1725870A1 (en) * 2004-03-18 2006-11-29 Applied Research Systems ARS Holding N.V. Anti-lipid rafts antibodies
EP1742941A1 (en) * 2004-04-22 2007-01-17 Transform Pharmaceuticals, Inc. Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US9663499B2 (en) 2013-06-07 2017-05-30 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
WO2016094570A1 (en) 2014-12-10 2016-06-16 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
WO2018190352A1 (ja) 2017-04-11 2018-10-18 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936470A (en) * 1975-01-27 1976-02-03 Janssen Pharmaceutica N.V. 1,3-Dioxolan-2-ylmethylimidazoles
US4101665A (en) * 1975-10-06 1978-07-18 Janssen Pharmaceutica N.V. 1-(2-Ar-4-aryloxymethyl-1,3-dioxolan-2-ylmethyl)imidazoles
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4321272A (en) * 1980-08-25 1982-03-23 Syntex (U.S.A.) Inc. Derivatives of substituted N-alkylimidazoles
DE3144318A1 (de) * 1981-11-07 1983-05-19 Bayer Ag, 5090 Leverkusen 2-imidazolylmethyl-2-phenyl-1, 3-dioxolane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
US4791111A (en) * 1985-12-23 1988-12-13 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
NZ278882A (en) * 1994-01-24 1997-06-24 Janssen Pharmaceutica Nv Piperazine-containing azole antifungal compounds

Also Published As

Publication number Publication date
HUP9801056A2 (hu) 1999-06-28
US6197972B1 (en) 2001-03-06
NZ305869A (en) 1998-08-26
IL117980A0 (en) 1996-08-04
HUP9801056A3 (en) 1999-09-28
HK1012186A1 (en) 1999-07-30
NO974690L (no) 1997-10-10
AU699313B2 (en) 1998-12-03
NO974690D0 (no) 1997-10-10
TW457240B (en) 2001-10-01
KR100413219B1 (ko) 2004-05-31
DK0871626T3 (da) 2002-02-25
ATE208386T1 (de) 2001-11-15
CZ291737B6 (cs) 2003-05-14
CA2217632A1 (en) 1996-10-24
CN1076727C (zh) 2001-12-26
KR19980703346A (ko) 1998-10-15
IL117980A (en) 2000-02-17
CZ328897A3 (cs) 1998-01-14
US5922718A (en) 1999-07-13
EP0871626A1 (en) 1998-10-21
NO312415B1 (no) 2002-05-06
JPH11503739A (ja) 1999-03-30
ES2167555T3 (es) 2002-05-16
WO1996033193A1 (en) 1996-10-24
DE69616825T2 (de) 2002-06-27
EP0871626B1 (en) 2001-11-07
DE69616825D1 (en) 2001-12-13
AU5399896A (en) 1996-11-07
CN1181079A (zh) 1998-05-06
PT871626E (pt) 2002-04-29
JP3782455B2 (ja) 2006-06-07
PL322872A1 (en) 1998-03-02
PL183737B1 (pl) 2002-07-31

Similar Documents

Publication Publication Date Title
HUP0201646A2 (hu) Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
MY102866A (en) Amide derivatives.
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
DE3766839D1 (de) 5,6-dihydro-2-(substituiertes phenyl)-1,2,4-triazin-3,5(2h,4h)-dione.
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
CA2203274A1 (en) Apolipoprotein-b synthesis inhibitors
MY132062A (en) Apolipoprotein-b synthesis inhibitors
ZA963152B (en) Novel triazolones as apolipoprotein-b synthesis inhibitors.
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
HUP0104308A2 (hu) Amidino- és guanidino-azetidinon-származékok, mint triptáz inhibitorok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
DE69323322D1 (de) Verwendung dimethylbenzofuran und dimethylbenzopyran derivate als 5-ht3 antagoniste
HUP0402515A2 (hu) Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
AP1396A (en) 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.
MY113584A (en) Prokinetic oxadiazoles
SE9904177D0 (sv) Novel compounds
DE69617001D1 (de) (2-morpholinylmethyl)benzamid-derivate
FI962120A0 (fi) Estramustiiniformulaatiot, joilla on parannetut farmaseuttiset ominaisuudet
MX9704667A (es) 6-[triazolil[3-trifluorometil)fenil]metil]-2-quinolinonas y quinolinotionas.
JO1648B1 (en) Nitrogen compounds
YU79401A (sh) Derivati 1-trifluorometil-4-hidroksi-7-piperidinil- aminometilhromana